

Breakthroughs and Views

Glucose-dependent insulintropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes

Victor A. Gault,* Peter R. Flatt, and Finbarr P.M. O'Harte

School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine BT52 1SA, Northern Ireland, UK

Received 17 June 2003

Abstract

Glucose-dependent insulintropic polypeptide (GIP) is a key incretin hormone, released postprandially into the circulation in response to feeding, producing a glucose-dependent stimulation of insulin secretion. It is this glucose-dependency that has attracted attention towards GIP as a potential therapeutic agent for the treatment of type 2 diabetes. A major drawback to achieving this goal has been the rapid degradation of circulating GIP by the ubiquitous enzyme, dipeptidylpeptidase IV (DPP IV). However, recent studies have described a number of novel structurally modified analogues of GIP with enhanced plasma stability, insulintropic and antihyperglycaemic activity. The purpose of this article was to provide an overview of the biological effects of several GIP modifications and to highlight the potential of such analogues in the treatment of type 2 diabetes and obesity.

© 2003 Elsevier Inc. All rights reserved.

Keywords: Dipeptidylpeptidase IV; Glucagon-like peptide-1; Glucose-dependent insulintropic polypeptide; GIP analogues; Insulin secretion; Obesity; Type 2 diabetes

Glucose-dependent insulintropic polypeptide (GIP) is a 42 amino acid gastrointestinal hormone secreted from enteroendocrine K-cells in response to food and nutrient absorption [1]. Although initially characterized for its ability to inhibit histamine-induced gastric acid secretion, the primary role of GIP as an incretin hormone moderating glucose-induced insulin secretion is widely recognized [2]. In addition to its actions on the pancreatic beta cell, GIP is also known to exert various extrapancreatic effects, which further enhance its glucose lowering ability. In particular, GIP has been shown to augment insulin-dependent inhibition of glycogenolysis in the liver [3] and to exert stimulatory effects on glucose uptake and metabolism in muscle [4]. Furthermore, functional GIP receptors have been identified on adipocytes [5] and have been shown to stimulate glucose transport [6], increase fatty acid synthesis [7], and stimulate lipoprotein lipase activity [8]. More recent studies have shown GIP to stimulate beta cell mitogenesis and inhibit apoptosis [9,10]. Consequently, this

wide spectrum of biological activities has sparked the recent interest in GIP as a novel therapeutic candidate for the treatment of type 2 diabetes [11].

Solutions to difficulties posed by GIP as a therapeutic agent

Currently there are two main concerns in attempting to utilize GIP as a potential therapeutic agent. First, the native peptide has a short biological half-life in the circulation (approximately 3–5 min), due primarily to degradation by the ubiquitous enzyme, dipeptidylpeptidase IV (DPP IV; EC 3.4.14.5). After release into the circulation, the native peptide (GIP 1-42) is rapidly hydrolysed at the amino terminus removing Tyr¹-Ala² to produce the truncated metabolite GIP(3-42) [12]. This major degradation product was initially thought to be inactive [13], however, recent observations have shown it to function as a GIP receptor antagonist *in vivo* [14]. To circumvent degradation, DPP IV inhibitors are currently being developed for *in vivo* administration. Several positive effects on glycaemic control have been

* Corresponding author. Fax: +44-28-7032-4965.

E-mail address: va.gault@ulster.ac.uk (V.A. Gault).

reported [15–17], but the effects of long-term interference on the metabolism of a plethora of other peptide substrates for DPP IV are as yet unknown [18]. Conceivably, a more attractive approach than widespread non-specific DPP IV inhibition involves the synthesis of specific GIP analogues modified at the enzyme cleavage site [11].

Another concern regarding the use of GIP in diabetes therapy stems from a study in which GIP was shown to exhibit marked reduction of insulinotropic activity in type 2 diabetic subjects [19]. Indeed, several studies have shown blunted insulin responses to GIP infusion in type 2 diabetes, albeit with differing degrees of beta cell resistance [19–22]. However, type 2 diabetes is associated with a global defect in insulin secretion not merely restricted to GIP, and encompassing other factors, including glucose and GLP-1 [23,24]. It has also been shown that beta cell sensitivity to GIP in type 2 diabetic patients improves with glyburide treatment [25]. Mutations of GIP receptors are rare in diabetes [21,26] and it is evident that any speculated abnormalities in GIP receptor binding can be overcome by enzyme-resistant analogues of GIP [11,27–33]. Furthermore, a recent study has shown that an N-terminally modified analogue of GIP, Tyr¹-glucitol-GIP, evokes a substantially larger and more protracted insulin response to oral glucose than the native GIP in type 2 diabetic patients [34].

The attractiveness and potential of stable GIP analogues

A number of significant features indicate that enzyme-resistant analogues of GIP have unique potential for diabetes therapy. First, GIP is the major physiological incretin as indicated by greater hormone responses to feeding [35] and comparative studies using either receptor antagonists [36,37] or receptor knockout mice [38,39]. Second, structural modification of the sister incretin, GLP-1, invariably compromises biological activity at the GLP-1 receptor [40–44], whereas the opposite is true for many analogues of GIP [11,27–33]. Third, any effect of GIP on increasing glucagon concentrations is only observed at normal glucose concentrations [45,46] and thus is irrelevant following feeding or in treating type 2 diabetes [47]. Fourth, in contrast to GLP-1, GIP lacks significant effects on gastric emptying and is therefore well tolerated by human subjects. This has become an increasing and possibly damning difficulty with the use of GLP-1 and its analogues in patients, as evidenced by increased gastrointestinal side effects and nausea [48]. This, therefore, focuses increasing attention on the antidiabetic potential of GIP. To date, several studies have been published examining the in vitro activities of a range of GIP fragments and analogues [27,49–54]. Moreover, as reviewed in the fol-

lowing sections, the in vivo antidiabetic potential of a family of selective designer human GIP 1–42 analogues (Fig. 1) modified at positions Tyr¹ [11,28–30], Ala² [31–33], and Glu³ [37,55] have been tested in animal models of type 2 diabetes and obesity.

Effects of modifications at position Tyr¹

Several novel Tyr¹-modified analogues of GIP have been developed, modelled on previous studies with the glucagon-secretin family of gastrointestinal peptides and knowledge of the substrate-binding specificity of DPP IV (Fig. 1). These analogues include *N*-acetyl-, *N*-Fmoc-, *N*-glucitol-, *N*-palmitate-, and *N*-pyroglutamyl-GIP [11,27–30]. All analogues modified at Tyr¹ exhibited complete resistance to DPP IV with in vitro half-lives greater than 24 h compared with 2.3 h for native GIP (Table 1), as illustrated for *N*-acetyl-GIP in Figs. 2A–B. This is in agreement with DPP IV substrate-binding specificity, which predicts the requirement for a bulky N-terminal amino acid (such as tyrosine in the case of GIP) possessing a free protonated α -amino group. By attaching amino acids or functional groups to the N-terminus of GIP, Tyr¹ becomes unprotonated, therefore, removing the explicit prerequisite required for DPP IV to act [18].

In assessing the biological activity of each analogue in vitro, cAMP formation in human GIP-receptor transfected cells [56] and insulinotropic activity in clonal BRIN-BD11 cells [57] was measured. All of the Tyr¹-modified analogues studied exhibited an increased potency (2- to 10-fold increase in EC₅₀ values) in stimulating cAMP production compared to native GIP (Table 1; Fig. 2C). Furthermore, the Tyr¹-modified analogues exhibited significantly increased insulin secretory responses (1.1- to 1.4-fold) compared to the native peptide in BRIN-BD11 cells, indicative of improved biological activity (Table 1; Fig. 2D). However, subtle differences could be observed within this group, as both *N*-Fmoc- and *N*-palmitate-GIP appeared to be moderately (14–20%) less potent in vitro than *N*-acetyl-, *N*-glucitol-, and *N*-pyroglutamyl-GIP.

In determining the insulin releasing and antihyperglycaemic potential of the GIP analogues in vivo, we used *ob/ob* mice, an extensively studied animal model of spontaneous obesity and diabetes. Characteristically these mice exhibit hyperphagia, marked obesity, moderate hyperglycaemia, and severe hyperinsulinaemia [28]. All of the Tyr¹-modified analogues were noticeably superior at stimulating insulin release (2.0- to 2.5-fold) and lowering blood glucose (1.4- to 1.9-fold) compared with native GIP (Table 1). Furthermore, it could be observed that *N*-acetyl-, *N*-glucitol-, and *N*-pyroglutamyl-GIP were slightly more potent than both *N*-Fmoc- and *N*-palmitate-GIP. Of the Tyr¹-modified analogues tested, *N*-acetyl-GIP [29] appeared to be the most




Fig. 1. A diagrammatic representation of the 42 amino acid sequence of human glucose-dependent insulinotropic polypeptide (GIP) with the solid arrow indicating the site of enzymatic degradation by dipeptidyl peptidase IV (DPP IV). The coloured amino acid residues (1–3) indicate the analogues synthesized and tested in animal models of obesity-diabetes [11,27–33], based on the entire human GIP 1–42 sequence.

impressive (Table 1). As shown in Fig. 3, this stable analogue significantly augmented the plasma insulin response and curtailed the glycaemic excursion following conjoint administration with glucose to obese diabetic *ob/ob* mice. The ability of *N*-acetyl-GIP to overcome the severe insulin resistance and beta cell defect (including poor response to native GIP) in this animal model is notable and affords proof of concept

that such analogues offer potential as future therapeutic agents for type 2 diabetes.

Effects of modifications at position Ala²

A series of Ala²-substituted analogues of GIP have also been synthesized and tested for their DPP IV

Table 1

Summary of the biological properties of designer human GIP analogues modified at the N-terminal Tyr¹, Ala² or Glu³ amino acid residues

Modification	Peptide	DPP IV half-life (h)	cAMP production EC ₅₀ (nmol/liter)	Maximal insulin response (% GIP max)	Plasma glucose AUC (% GIP max response)	Plasma insulin AUC (% GIP max response)
Native hormone	GIP	2.3	18.2	100 ± 3.1	100	100
Tyr ¹ -modification	<i>N</i> -Acetyl-GIP	>24	1.86	127 ± 4.0	62	251
	<i>N</i> -Glucitol-GIP	>24	2.03	141 ± 8.1	57	236
	<i>N</i> -Pyroglutamyl-GIP	>24	2.67	118 ± 1.6	61	224
	<i>N</i> -Palmitate-GIP	>24	10.0	122 ± 3.3	69	206
	<i>N</i> -Fmoc-GIP	>24	9.4	112 ± 2.5	69	208
Ala ² -substitution	(Gly ²)GIP	>8	15.0	107 ± 6.4	81	144
	(Ser ²)GIP	4.8	14.9	140 ± 4.7	75	126
	(Abu ²)GIP	1.9	38.5	62 ± 0.6	94	79
	(Sar ²)GIP	1.6	54.6	42 ± 3.8	106	96
Glu ³ -substitution	(Pro ³)GIP	>24	Nil	52 ± 2.2	160	43

DPP IV half-lives were calculated by plotting the percentage of intact peptide remaining after incubation with DPP IV ($n = 3$) versus incubation time. EC₅₀ values were calculated from cAMP dose–response curves ($n = 3$) in human GIP-receptor transfected CHL cells using Graph pad Prism. Maximal insulin response values in BRIN-BD11 cells ($n = 8$) were calculated relative to the maximal percentage GIP response. Plasma glucose and insulin AUC values from *ob/ob* mice ($n = 7–8$) were calculated and recorded as a percentage of the maximal GIP response. Values represent means ± SEM. Data taken from [11,27–33].




Fig. 2. (A,B) Representative HPLC profiles obtained after incubation of native GIP (A) and *N*-acetyl-GIP (B) with DPP IV for 2h. Reaction products were separated on a Vydac C-18 column and peaks corresponding to intact GIP, *N*-acetyl-GIP, and GIP(3-42) are indicated. (C) Dose-dependent production of cAMP by native GIP and *N*-acetyl-GIP upon binding to CHL cells stably transfected with the human GIP receptor. (D) Dose-dependent effects of GIP and *N*-acetyl-GIP on insulin secretion from BRIN-BD11 cells. Values are means ± SEM (*n* = 3–8). ***P* < 0.01, ****P* < 0.001 compared to control. ^Δ*P* < 0.05 and ^{ΔΔΔ}*P* < 0.01 compared to native GIP. Data taken from [29].




Fig. 3. Plasma glucose and insulin responses of 18 h fasted obese diabetic (*ob/ob*) mice after intraperitoneal administration of glucose alone (2 g/kg body weight; open circles), or in combination with either 25 nmol/kg GIP (solid squares) or *N*-acetyl-GIP (open triangles). Values are means ± SEM (*n* = 7–8). **P* < 0.05, ***P* < 0.01, and ****P* < 0.001 compared to glucose alone. ^Δ*P* < 0.05, ^{ΔΔ}*P* < 0.01, and ^{ΔΔΔ}*P* < 0.001 compared to GIP. Data taken from [29].

stability and biological activity (Fig. 1). These include (Abu²)GIP, (Gly²)GIP, (Sar²)GIP, (Ser²)GIP, and (D-Ala²)GIP [31–33]. Substitution of Ala² with either 2-aminobutyric acid (Abu) or sarcosine (Sar) did not appear to confer any increased resistance against DPP IV, as both analogues followed similar or slightly accelerated patterns of degradation to the native peptide (Table 1) [32]. Indeed, both of these substitutions impaired biological activity compared with native GIP when tested using the in vitro insulin secretion and cAMP models. Surprisingly though, both analogues displayed antihyperglycaemic and insulinotropic activity comparable to native GIP when administered to obese diabetic *ob/ob* mice (Table 1) [32].

In sharp contrast, substitution with either a glycine (Gly) or serine (Ser) residue for Ala² [31] produced more stable analogues with significantly prolonged DPP IV half-lives compared with native GIP (Table 1). Unlike the Abu and Sar substitutions, both (Gly²)GIP and (Ser²)GIP displayed enhanced abilities to elevate cAMP (1.2-fold increase in EC₅₀ values) and stimulate insulin secretion (1.2- to 1.4-fold) in vitro (Table 1). When tested in obese diabetic *ob/ob* mice, both analogues exhibited significantly improved insulinotropic activity (1.3- to 1.5-fold) and antihyperglycaemic activity (1.2- to 1.3-fold) compared with native GIP (Table 1), further supporting the idea that DPP IV resistant analogues of GIP may prove useful in the treatment of type 2 diabetes [31].

Using a similar approach, the research group of Pederson and McIntosh [33] recently investigated substitution of the L-alanine in position 2 of GIP with D-alanine. This enzyme resistant analogue exhibited moderately reduced biological activity in vitro, although it significantly decreased the glycaemic excursion (1.6-fold) in *fal/fa* VDF Zucker rats with an efficacy similar to that seen with either (Gly²)GIP or (Ser²)GIP [31]. However, while several of these Ala²-substituted analogues demonstrated significantly improved biological activity compared with native GIP, their efficacy was not as impressive as that of the Tyr¹-modified analogues (Table 1).

Effects of modification at position Glu³

Substitution of Glu³ in GIP with a proline (Pro) residue [55] produced a novel GIP analogue, (Pro³)GIP (Fig. 1), completely resistant to DPP IV (Table 1). Surprisingly though, (Pro³)GIP inhibited GIP-stimulated cAMP production and insulin secretion with high sensitivity and specificity in vitro (Table 1). Furthermore, studies using *ob/ob* mice showed that (Pro³)GIP effectively and specifically countered the insulin releasing and antihyperglycaemic actions of the native peptide in vivo [37,55], reminiscent of the effects of the major

DPP IV degradation product, GIP(3-42) [14]. (Pro³)GIP has also recently been utilized to demonstrate that GIP is the major physiological incretin, accounting for approximately 80% of nutrient-induced enteroinsular pancreatic beta cell stimulation [37].

Interestingly, the therapeutic potential of such a selective GIP receptor antagonist has recently been demonstrated in a study by Miyawaki and colleagues [58], where they showed that GIP plays a central role in lipid metabolism and in the development of both genetically inherited and diet-induced obesity. Thus, growing evidence supports the long-held view that GIP is an important factor directly linking over-nutrition to fat deposition, obesity, and glucose intolerance [59,60].

Conclusion

Structural modification of GIP at Tyr¹, Ala² or Glu³ resulted in analogues with greatly increased, moderately increased or antagonistic biological properties, respectively, both in vitro and in vivo. The Tyr¹-modified analogues, especially *N*-acetyl-GIP, exhibit a substantially enhanced potency and duration of action compared to native GIP. Accordingly, these novel agents provide the basis for exploration to realize the potential of GIP in diabetes therapy. However, despite the tremendous potential for GIP analogues in the treatment of diabetes-obesity, their peptidic nature effectively rules out the option of straightforward oral administration. Therefore, in order to further develop rational drug design for GIP, information on appropriate delivery systems, three-dimensional structure and molecular interactions of the peptide with its receptor are essential.

Acknowledgments

We dedicate this paper to Professor Vincent Marks who has been a great inspiration and long-term enthusiast of GIP. The authors' work was supported financially by University of Ulster Research Strategy Funding and the Research and Development Office of Health and Personal Social Services for Northern Ireland.

References

- [1] J.C. Brown, Enteroinsular axis, in: G.J. Dockray, J.H. Walsh (Eds.), *Gut Peptides: Biochemistry and Physiology*, Raven Press, New York, 1994, pp. 765–784.
- [2] W. Creutzfeldt, The entero-insular axis in type 2 diabetes— incretins as therapeutic agents, *Exp. Clin. Endocrinol. Diabetes* 109 (2001) 288–303.
- [3] D. Elahi, G.S. Meneilly, K.L. Minaker, J.W. Rowe, D.K. Andersen, Regulation of hepatic glucose production by gastric inhibitory polypeptide in man, in: *Proceedings of the Sixth International Conference on Gastrointestinal Hormones*, Ottawa, 1986, p. 18.

- [4] F.P.M. O'Harte, A.M. Gray, P.R. Flatt, Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle, *J. Endocrinol.* 156 (1998) 237–243.
- [5] R.G.-C. Yip, M.O. Boylan, T.J. Kieffer, M.M. Wolfe, Functional GIP receptors are present on adipocytes, *Endocrinology* 139 (1998) 4004–4007.
- [6] R.H. Eckel, W.J. Fujimoto, J.D. Brunzell, Gastric inhibitory polypeptide enhances lipoprotein lipase activity in cultured preadipocytes, *Diabetes* 28 (1979) 1141–1142.
- [7] J. Oben, L. Morgan, J. Fletcher, V. Marks, Effects of the enteropancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1 (7-36) amide on fatty acid synthesis in explants of rat adipose tissue, *J. Endocrinol.* 130 (1991) 267–272.
- [8] J.M. Knapper, S.M. Puddicombe, L.M. Morgan, J.M. Fletcher, Investigation into the actions of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1(7-36)amide on lipoprotein lipase activity in explants of rat tissue, *J. Nutr.* 125 (1995) 183–188.
- [9] A. Trümper, K. Trümper, H. Trusheim, R. Arnold, B. Göke, D. Horsch, Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling, *Mol. Endocrinol.* 15 (2001) 1559–1570.
- [10] J. Ehses, V. Casilla, T. Doty, J.A. Pospisilik, H.-U. Demuth, R.A. Pederson, C.H.S. McIntosh, Glucose-dependent insulinotropic polypeptide (GIP) stimulates cell growth and promotes cell survival in INS-1 cells [abstract], *Diabetes* 51 (Suppl. 2) (2002) A339.
- [11] F.P.M. O'Harte, M.H. Mooney, P.R. Flatt, N-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycaemic activity, *Diabetes* 48 (1999) 758–765.
- [12] T.J. Kieffer, C.H.S. McIntosh, R.A. Pederson, Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV, *Endocrinology* 136 (1995) 3585–3596.
- [13] J.C. Brown, M. Dahl, S. Kwauk, C.H.S. McIntosh, S.C. Otte, R.A. Pederson, Actions of GIP, *Peptides* 2 (1981) 241–245.
- [14] V.A. Gault, J.C. Parker, P. Harriott, P.R. Flatt, F.P.M. O'Harte, Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide (GIP), GIP(3-42), is a GIP receptor antagonist in vivo, *J. Endocrinol.* 175 (2002) 525–533.
- [15] C.F. Deacon, P. Danielsen, L. Klarskov, M. Olesen, J.J. Holst, Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs, *Diabetes* 50 (2001) 1588–1597.
- [16] J.A. Pospisilik, S.G. Stafford, H.-U. Demuth, R. Brownsey, W. Parkhouse, D.T. Finegood, C.H.S. McIntosh, R.A. Pederson, Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β -cell glucose responsiveness in VDF (*fa/fa*) Zucker rats, *Diabetes* 51 (2002) 943–950.
- [17] B. Ahren, E. Simonsson, H. Larsson, M. Landin-Olsson, H. Torgeirsson, P.A. Jansson, M. Sandqvist, P. Bavenholm, S. Efendic, J.W. Eriksson, S. Dickinson, D. Holmes, Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes, *Diabetes Care* 25 (2002) 869–875.
- [18] R. Mentlein, Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides, *Regul. Pept.* 85 (1999) 9–24.
- [19] M.A. Nauck, M.M. Heimesaat, C. Ørskov, J.J. Holst, R. Ebert, W. Creutzfeldt, Preserved incretin activity of glucagon-like peptide-1 (7-36amide), but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus, *J. Clin. Invest.* 91 (1993) 301–307.
- [20] M. Nauck, R. Stockman, R. Ebert, W. Creutzfeldt, Reduced incretin effect in type 2 (non-insulin-dependent) diabetes, *Diabetologia* 29 (1986) 46–52.
- [21] D. Elahi, M. McAloon-Dyke, N. Fukagawa, G. Meneilly, A. Sclater, K. Minaker, J. Habener, D. Andersen, The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects, *Regul. Pept.* 51 (1994) 63–74.
- [22] I.R. Jones, D.R. Owens, A.J. Moody, S.D. Luzio, T. Morris, T.M. Hayes, The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion, *Diabetologia* 30 (1987) 707–712.
- [23] L.L. Kjemis, J.J. Holst, A. Volund, S. Madsbad, The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects, *Diabetes* 52 (2003) 380–386.
- [24] W.K. Ward, D.C. Bolgiano, B. McKnight, J.B. Halter, D. Porte Jr., Diminished B cell capacity in patients with noninsulin-dependent diabetes mellitus, *J. Clin. Invest.* 74 (1984) 1318–1328.
- [25] G.S. Meneilly, M. Bryer-Ash, D. Elahi, The effect of glyburide on beta-cell sensitivity to glucose-dependent insulinotropic polypeptide, *Diabetes Care* 16 (1993) 110–114.
- [26] K. Almind, L. Ambye, S.A. Urhammer, T. Hansen, S.M. Echwald, J.J. Holst, J. Gromada, B. Thorens, O. Pedersen, Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells, *Diabetologia* 41 (1998) 1194–1198.
- [27] F.P.M. O'Harte, Y.H.A. Abdel-Wahab, J.M. Conlon, P.R. Flatt, Amino-terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells, *Biochim. Biophys. Acta* 1425 (1998) 319–327.
- [28] F.P.M. O'Harte, M.H. Mooney, C.M.N. Kelly, P.R. Flatt, Improved glycaemic control in obese diabetic *ob/ob* mice using N-terminally modified gastric inhibitory polypeptide, *J. Endocrinol.* 165 (2000) 639–648.
- [29] F.P.M. O'Harte, V.A. Gault, J.C. Parker, P. Harriott, M.H. Mooney, C.J. Bailey, P.R. Flatt, Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of glucose-dependent insulinotropic polypeptide: N-acetyl-GIP and pGlu-GIP, *Diabetologia* 45 (2002) 1281–1291.
- [30] V.A. Gault, P.R. Flatt, C.J. Bailey, P. Harriott, B. Greer, M.H. Mooney, F.P.M. O'Harte, Enhanced cyclic AMP generation and insulin-releasing potency of two novel N-terminal Tyr¹-modified enzyme resistant forms of GIP, is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes, *Biochem. J.* 367 (2002) 913–920.
- [31] V.A. Gault, P.R. Flatt, P. Harriott, M.H. Mooney, C.J. Bailey, F.P.M. O'Harte, Improved biological activity of Gly²- and Ser²-substituted analogues of glucose-dependent insulinotropic polypeptide, *J. Endocrinol.* 176 (2003) 133–141.
- [32] V.A. Gault, F.P.M. O'Harte, P. Harriott, P.R. Flatt, Degradation, cyclic AMP production, insulin secretion and glycemic effects of two novel N-terminal Ala²-substituted analogs of GIP with preserved biological activity in vivo, *Metabolism* 52 (2003) 679–687.
- [33] S.A. Hinke, R.W. Gelling, R.A. Pederson, S. Manhart, C. Nian, H.-U. Demuth, C.H.S. McIntosh, Dipeptidyl peptidase IV-resistant [D-Ala²]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats, *Diabetes* 51 (2002) 656–661.
- [34] J.R. Lindsay, S.T.B. Au, C.M.N. Kelly, F.P.M. O'Harte, P.R. Flatt, P.M. Bell, A novel amino-terminally glycosylated analogue of glucose-dependent insulinotropic polypeptide (GIP), with

- prolonged insulinotropic activity in type 2 diabetes mellitus [abstract], *Diabetes* 51 (Suppl. 2) (2002) A85.
- [35] J.J. Meier, M.A. Nauck, W.E. Schmidt, B. Gallwitz, Gastric inhibitory polypeptide: the neglected incretin revisited, *Regul. Pept.* 107 (2002) 1–7.
- [36] C.-C. Tseng, X.-Y. Zhang, M.M. Wolfe, Effect of GIP and GLP-1 antagonists on insulin release in the rat, *Am. J. Physiol.* 276 (1999) 1049–1054.
- [37] V.A. Gault, P.R. Flatt, P. Harriott, B.D. Green, F.P.M. O'Harte, Effects of the novel (Pro³)GIP antagonist and exendin (9-39) amide on GIP and GLP-1 induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (*ob/ob*) mice: evidence that GIP is the major physiological incretin, *Diabetologia* 46 (2003) 222–230.
- [38] R.A. Pederson, M. Satkunarajah, C.H.S. McIntosh, L.A. Scrocchi, D. Flamez, F. Schuit, D.J. Drucker, M.B. Wheeler, Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor $-/-$ mice, *Diabetes* 47 (1998) 1046–1052.
- [39] K. Miyawaki, Y. Yamada, H. Yano, H. Niwa, N. Ban, Y. Ihara, A. Kubota, S. Fujimoto, M. Kajikawa, A. Kuroe, K. Tsuda, H. Hashimoto, T. Yamashita, T. Jomori, F. Tashiro, J.I. Miyazaki, Y. Seino, Glucose tolerance caused by a defect in the enteroinsular axis: a study in gastric inhibitory polypeptide receptor knockout mice, *Proc. Natl. Acad. Sci. USA* 96 (1999) 14843–14847.
- [40] R. Burcelin, W. Dolci, B. Thorens, Long-lasting antidiabetic effects of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1, *Metabolism* 48 (1999) 252–258.
- [41] E.G. Siegel, B. Gallwitz, G. Scharf, R. Mentlein, C. Morys-Wortmann, U.R. Folsch, J. Schrezenmeir, K. Drescher, W.E. Schmidt, Biological activity of GLP-1 analogues with N-terminal modifications, *Regul. Pept.* 79 (1999) 93–102.
- [42] Q. Xiao, J. Giguere, M. Parisien, W. Jeng, S.A. St-Pierre, P.L. Brubaker, M.B. Wheeler, Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo, *Biochemistry* 40 (2001) 2860–2869.
- [43] B. Gallwitz, T. Ropeter, C. Morys-Wortmann, R. Mentlein, E.G. Siegel, W.E. Schmidt, GLP-1 analogues resistant to degradation by dipeptidyl-peptidase IV in vitro, *Regul. Pept.* 86 (2000) 103–111.
- [44] C.F. Deacon, L.B. Knudsen, K. Madsen, F.C. Wiberg, O. Jacobsen, J.J. Holst, Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity, *Diabetologia* 41 (1998) 271–278.
- [45] R.A. Pederson, J.C. Brown, Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas, *Endocrinology* 103 (1978) 610–615.
- [46] J.J. Meier, B. Gallwitz, N. Siepmann, J.J. Holst, C.F. Deacon, W.E. Schmidt, M.A. Nauck, Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects as euglycaemia, *Diabetologia* 46 (2003) 798–801, DOI 10.1007/s00125-003-1103-y.
- [47] B. Kreymann, G. Williams, M.A. Ghatei, S.R. Bloom, Glucagon-like peptide-1 7-36: a physiological incretin in man, *Lancet* 2 (1987) 1300–1304.
- [48] C.B. Juhl, M. Hollingdal, J. Sturis, G. Jakobsen, H. Agersø, J. Veldhuis, N. Pørksen, O. Schmitz, Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes, *Diabetes* 51 (2002) 424–429.
- [49] V.A. Gault, P. Harriott, P.R. Flatt, F.P.M. O'Harte, Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, *Biosci. Rep.* 22 (2002) 523–528.
- [50] V.A. Gault, N. Irwin, P. Harriott, P.R. Flatt, F.P.M. O'Harte, DPP IV resistance and insulin releasing activity of a novel disubstituted analogue of glucose-dependent insulinotropic polypeptide, (Ser²-Asp¹³)GIP, *Cell Biol. Int.* 27 (2003) 41–46.
- [51] K. Kühn-Wache, S. Manhart, T. Hoffmann, S.A. Hinke, R. Gelling, R.A. Pederson, C.H.S. McIntosh, H.-U. Demuth, Synthesis of analogs of glucose-dependent insulinotropic polypeptide with increased dipeptidyl peptidase IV resistance, *Adv. Exp. Med. Biol.* 477 (2000) 187–195.
- [52] S.A. Hinke, R. Gelling, S. Manhart, F. Lynn, R.A. Pederson, K. Kühn-Wache, F. Rosche, H.-U. Demuth, D. Coy, C.H.S. McIntosh, Structure-activity relationships of glucose-dependent insulinotropic polypeptide (GIP), *Biol. Chem.* 384 (2003) 403–407.
- [53] S. Manhart, S.A. Hinke, C.H. McIntosh, R.A. Pederson, H.U. Demuth, Structure-function analysis of a series of novel GIP analogues containing different helical length linkers, *Biochemistry* 42 (2003) 3081–3088.
- [54] S.A. Hinke, S. Manhart, N. Pamir, H. Demuth, R.W. Gelling, R.A. Pederson, C.H. McIntosh, Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP), *Biochim. Biophys. Acta* 1547 (2001) 143–155.
- [55] V.A. Gault, F.P.M. O'Harte, P. Harriott, P.R. Flatt, Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide, *Biochem. Biophys. Res. Commun.* 290 (2002) 1420–1426.
- [56] S. Gremlich, A. Porret, E.H. Hani, D. Cherif, N. Vionnet, P. Froguel, B. Thorens, Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor, *Diabetes* 44 (1995) 1202–1208.
- [57] N.H. McClenaghan, C.R. Barnett, E. Ah-Sing, Y.H.A. Abdel-Wahab, F.P.M. O'Harte, T.-W. Yoon, S.K. Swanston-Flatt, P.R. Flatt, Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion, *Diabetes* 45 (1996) 1132–1140.
- [58] K. Miyawaki, Y. Yamada, N. Ban, Y. Ihara, K. Tsukiyama, K. Zhou, S. Fujimoto, A. Oku, K. Tsuda, S. Toyokuni, H. Hiai, W. Mizunoya, T. Fushiki, J.J. Holst, M. Makino, A. Tashita, Y. Kobara, Y. Tsubamoto, T. Jinnouchi, T. Jomori, Y. Seino, Inhibition of gastric inhibitory polypeptide signaling prevents obesity, *Nat. Med.* 8 (2002) 738–742.
- [59] P.R. Flatt, C.J. Bailey, P. Kwasowski, S.K. Swanston-Flatt, V. Marks, Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice, *Diabetes* 32 (1983) 433–435.
- [60] C.J. Bailey, P.R. Flatt, P. Kwasowski, C.J. Powell, V. Marks, Immunoreactive gastric inhibitory polypeptide and K-cell hyperplasia in obese hyperglycaemic (*ob/ob*) mice fed a high fat and high carbohydrate cafeteria diets, *Acta Endocrinol.* 112 (1986) 224–229.